col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

Springer Science and Business Media LLC: npj Vaccines
  original article Date Title Authors   All Authors
1 [GO] 2021―Jun―17 A cautionary perspective regarding the isolation and serial propagation of SARS-CoV-2 in Vero cells Simon G. P. Funnell, Babak Afrough, John James Baczenas, Neil Berry, Kevin R. Bewley, Rebecca Bradford, et al. (+11)
2 [GO] 2021―May―14 Public attitudes toward COVID-19 vaccination: The role of vaccine attributes, incentives, and misinformation Sarah Kreps, Nabarun Dasgupta, John S. Brownstein, Yulin Hswen, Douglas L. Kriner
3 [GO] 2021―May―13 Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation Lauren M. Meyers, Andres H. Gutiérrez, Christine M. Boyle, Frances Terry, Bethany G. McGonnigal, Andres Salazar, et al. (+4)
4 [GO] 2021―May―13 Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2 Ian McDonald, Sam M. Murray, Catherine J. Reynolds, Daniel M. Altmann, Rosemary J. Boyton
5 [GO] 2021―May―10 ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets Glenn A. Marsh, Alexander J. McAuley, Gough G. Au, Sarah Riddell, Daniel Layton, Nagendrakumar B. Singanallur, et al. (+38)
6 [GO] 2021―Apr―22 Recommendations for acceleration of vaccine development and emergency use filings for COVID-19 leveraging lessons from the novel oral polio vaccine Natalie Thiel, Casey Selwyn, Georgina Murphy, Shmona Simpson, Ajoy C. Chakrabarti
7 [GO] 2021―Apr―21 Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases Velayudhan Mohan Kumar, Seithikurippu R. Pandi-Perumal, Ilya Trakht, Sadras Panchatcharam Thyagarajan
8 [GO] 2021―Apr―19 Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models Kirill V. Kalnin, Timothy Plitnik, Michael Kishko, Jinrong Zhang, Donghui Zhang, Adrien Beauvais, et al. (+32)
9 [GO] 2021―Apr―16 mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents Susanne Rauch, Nicole Roth, Kim Schwendt, Mariola Fotin-Mleczek, Stefan O. Mueller, Benjamin Petsch
10 [GO] 2021―Apr―14 Access to and equitable distribution of COVID-19 vaccine in low-income countries Krishna Prasad Acharya, Tirth Raj Ghimire, Supram Hosuru Subramanya
11 [GO] 2021―Apr―13 Considerations for bioanalytical characterization and batch release of COVID-19 vaccines Gautam Sanyal, Anna Särnefält, Arun Kumar
12 [GO] 2021―Mar―30 Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters Qingmei Jia, Helle Bielefeldt-Ohmann, Rachel M. Maison, Saša Masleša-Galić, Sarah K. Cooper, Richard A. Bowen, Marcus A. Horwitz
13 [GO] 2021―Mar―25 The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization Jing Zou, Xuping Xie, Camila R. Fontes-Garfias, Kena A. Swanson, Isis Kanevsky, Kristin Tompkins, et al. (+4)
14 [GO] 2021―Mar―19 Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease Joan E. M. van der Lubbe, Sietske K. Rosendahl Huber, Aneesh Vijayan, Liesbeth Dekking, Ella van Huizen, Jessica Vreugdenhil, et al. (+21)
15 [GO] 2021―Mar―19 Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2 Hansam Cho, Yuyeon Jang, Ki-Hoon Park, Hanul Choi, Aleksandra Nowakowska, Hee-Jung Lee, et al. (+6)
16 [GO] 2021―Feb―22 SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates Nikolaos C. Kyriakidis, Andrés López-Cortés, Eduardo Vásconez González, Alejandra Barreto Grimaldos, Esteban Ortiz Prado
17 [GO] 2021―Feb―11 Promoting versatile vaccine development for emerging pandemics Joshua T. Monrad, Jonas B. Sandbrink, Neil G. Cherian
18 [GO] 2021―Jan―25 Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters Rebecca L. Brocato, Steven A. Kwilas, Robert K. Kim, Xiankun Zeng, Lucia M. Principe, Jeffrey M. Smith, Jay W. Hooper
19 [GO] 2021―Jan―04 SARS-CoV-2 structural features may explain limited neutralizing-antibody responses Martin F. Bachmann, Mona O. Mohsen, Lisha Zha, Monique Vogel, Daniel E. Speiser
20 [GO] 2020―Nov―03 Plasma-based COVID-19 treatments in low-and middle-income countries and the risk of transfusion-transmitted infections Jay Epstein, W. Martin Smid, Silvano Wendel, Daniel Somuah, Thierry Burnouf
21 [GO] 2020―Oct―23 Navigating facilitated regulatory pathways during a disease X pandemic Shmona Simpson, Ajoy Chakrabarti, David Robinson, Keith Chirgwin, Murray Lumpkin
22 [GO] 2020―Oct―16 Rabies virus-based COVID-19 vaccine CORAVAX™ induces high levels of neutralizing antibodies against SARS-CoV-2 Drishya Kurup, Christoph Wirblich, Holly Ramage, Matthias J. Schnell
23 [GO] 2020―Oct―08 Experimental and in silico evidence suggests vaccines are unlikely to be affected by D614G mutation in SARS-CoV-2 spike protein Alexander J. McAuley, Michael J. Kuiper, Peter A. Durr, Matthew P. Bruce, Jennifer Barr, Shawn Todd, et al. (+14)
24 [GO] 2020―Sep―28 Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses Rinke Bos, Lucy Rutten, Joan E. M. van der Lubbe, Mark J. G. Bakkers, Gijs Hardenberg, Frank Wegmann, et al. (+18)
25 [GO] 2020―Sep―04 Impact of glycan cloud on the B-cell epitope prediction of SARS-CoV-2 Spike protein René Wintjens, Amanda Makha Bifani, Pablo Bifani
26 [GO] 2020―Jul―27 Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19 Simon P. Graham, Rebecca K. McLean, Alexandra J. Spencer, Sandra Belij-Rammerstorfer, Daniel Wright, Marta Ulaszewska, et al. (+36)
27 [GO] 2020―Jul―06 Plasma-based COVID-19 treatments in low- and middle-income nations pose a high risk of an HIV epidemic Leonardo M. R. Ferreira, Mohammed A. Mostajo-Radji
28 [GO] 2020―Jun―15 Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens Jayanthi Wolf, Samantha Bruno, Michael Eichberg, Risat Jannat, Sharon Rudo, Susan VanRheenen, Beth-Ann Coller
29 [GO] 2020―May―28 Universal coronavirus vaccines: the time to start is now Luca T. Giurgea, Alison Han, Matthew J. Memoli
30 [GO] 2020―May―25 Certainty of success: three critical parameters in coronavirus vaccine development David C. Kaslow
31 [GO] 2020―Apr―30 COVID-19 vaccines: breaking record times to first-in-human trials Young Chan Kim, Barbara Dema, Arturo Reyes-Sandoval
32 [GO] 2020―Mar―06 The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines Weilong Shang, Yi Yang, Yifan Rao, Xiancai Rao
33 [GO] 2019―Dec―06 Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts Raffael Nachbagauer, Bruno Salaun, Daniel Stadlbauer, Mohammad A. Behzadi, Damien Friel, Arvind Rajabhathor, et al. (+11)


[de][en]

Last change 2021―Jun―30 20:09:44 UTC

© Daten-Quadrat 2021       Done in 0.010 sec